Munich Court Lifts Germany Ban on Keytruda SC, Clearing Way for Distribution
Key Facts
On November 19, 2026, the Munich Higher Regional Court lifted a preliminary injunction issued in December 2025 that had barred Merck from distributing and offering Keytruda SC in Germany, according to a Halozyme statement. The ruling allows the company to resume distribution in the German market after the ban was lifted. But the decision did not end the patent dispute between the two companies. Mark Snyder, Halozyme’s chief legal officer, said the company “disagrees with the decision and will immediately file a patent infringement suit against Merck in Germany seeking permanent relief.” He added that the appeal decision does not prevent it from pursuing the suit.
The German ruling marks a shift in one market in the dispute, while other court orders continue to limit the availability of the subcutaneous version in Europe. Merck said in its quarterly filing that a court in The Hague issued an order on October 7 barring continued sales of Keytruda SC in Denmark and Italy and preventing its launch in the Netherlands, Belgium, Ireland and France. Halozyme said the Hague order also covered Sweden and Switzerland, and that the court found Merck had infringed the company’s European patent EP 2,797,622. Halozyme said the court rejected Merck’s argument that the patent was invalid. The Munich ruling therefore affects only the German order it lifted, while litigation over other markets continues.
The case concerns the method of administering the subcutaneous version of Keytruda, a different formulation from the well-known intravenous treatment. The European Commission approved the subcutaneous administration route and the new pharmaceutical form in November 2025 for use across Keytruda indications for adults in Europe, according to Merck. The company said, however, that the timing of commercial availability varies among EU countries and depends on completion of reimbursement procedures and the outcome of the legal dispute with Halozyme. Halozyme said the technology at issue was developed through research involving nearly 7,000 modifications to human hyaluronidase enzymes. These enzymes, according to the company, enable a mechanism for rapid subcutaneous delivery of treatments.
The dispute does not cover every form of treatment: Halozyme said patients will continue to have access to intravenous Keytruda because it is not covered by its patent or the Hague court order. The case comes as Keytruda remains one of the products investors track in Merck’s results: combined global sales of Keytruda and Keytruda Qlex rose 6% in the third quarter of 2026 and 7% in the first nine months of the year, according to the company’s filing. Merck attributed U.S. demand growth to increased use in early-stage cancer indications. Those indications included some types of triple-negative breast cancer, bladder cancer, head and neck cancer, and cervical cancer. Merck shares closed at $132.81 on November 19, according to EL7 data.
The dispute also involves patent proceedings in the United States and Europe. Merck said Halozyme filed a lawsuit in New Jersey in April 2025 alleging that the company’s activities related to subcutaneous pembrolizumab infringe or will infringe 15 patents in the MDASE portfolio. Merck said it began filing petitions in November 2024 to challenge the validity of patents in the portfolio. According to its filing, the Patent Trial and Appeal Board issued final decisions in 11 petitions and found every challenged claim unpatentable; one Halozyme request for review also remained pending. The German ruling adds a new national track to this multi-jurisdictional dispute, as Halozyme prepares to seek permanent relief in German court.
Attention now turns to court dates scheduled for the following weeks. According to Merck’s filing, a UK trial was scheduled to begin on November 30, 2026, to consider the validity of patent EP347 and its alleged infringement. An initial hearing in Italy on Halozyme’s court application was also scheduled for December 2. Meanwhile, Merck said the timing of Keytruda SC’s commercial availability varies by country and is tied, among other factors, to reimbursement procedures and litigation outcomes. The intravenous version remains available to patients, according to Halozyme, as proceedings continue to determine the scope of access to the subcutaneous formulation in Europe.